A novel platform to produce human monoclonal antibodies

References

• Frost & Sullivan. Antibody Technology Developments (Technical Insights) 2005; 30
   Google Scholar
• Chames P, Van Regenmortel M, Weiss E, Baty D. Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol 2009; 157:220 - 233
   PubMed Web of Science ®Google Scholar
• Smith SL. Ten years of Orthoclone OKT3 (muromonab-CD3): a review. J Transpl Coord 1996; 6:109 - 119
   PubMedGoogle Scholar
• Aggarwal S. What's fueling the biotech engine—2009–2010. Nat Biotech 2010; 28:1165 - 1171
   PubMed Web of Science ®Google Scholar
• Scolnik PA. mAbs: a business perspective. mAbs 2009; 1:179 - 184
   PubMed Web of Science ®Google Scholar
• Neuberger MS, Williams GT, Mitchell EB, Jouhal SS, Flanagan JG, Rabbitts TH. A hapten-specific chimaeric IgE antibody with human physiological effector function. Nature 1985; 314:268 - 270
   PubMed Web of Science ®Google Scholar
• Jones PT, Dear PH, Foote J, Neuberger MS, Winter G. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 1986; 321:522 - 525
   PubMed Web of Science ®Google Scholar
• Reichert JM, Rosensweig CJ, Faden LB, Dewitz MC. Monoclonal antibody successes in the clinic. Nat Biotechnol 2005; 23:1073 - 1078
   PubMed Web of Science ®Google Scholar
• Presta LG. Engineering of therapeutic antibodies to minimize immunogenicity and optimize function. Adv Drug Deliv Rev 2006; 58:640 - 656
   PubMed Web of Science ®Google Scholar
• Hoet RM, Cohen EH, Kent RB, Rookey K, Schoonbroodt S, Hogan S, et al. Generation of high-affinity human antibodies by combining donor-derived and synthetic complementarity-determining-region diversity. Nat Biotechnol 2005; 23:344 - 348
   PubMed Web of Science ®Google Scholar
• Rothe C, Urlinger S, Lohning C, Prassler J, Stark Y, Jager U, et al. The human combinatorial antibody library HuCAL GOLD combines diversification of all six CDRs according to the natural immune system with a novel display method for efficient selection of high-affinity antibodies. J Mol Biol 2008; 376:1182 - 1200
   PubMed Web of Science ®Google Scholar
• Chao G, Lau WL, Hackel BJ, Sazinsky SL, Lippow SM, Wittrup KD. Isolating and engineering human antibodies using yeast surface display. Nat Protoc 2006; 1:755 - 768
   PubMed Web of Science ®Google Scholar
• Lonberg N. Human monoclonal antibodies from transgenic mice. Handb Exp Pharmacol 2008; 69 - 97
   PubMedGoogle Scholar
• Nelson AL, Dhimolea E, Reichert JM. Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov 2010; 9:767 - 774
   PubMed Web of Science ®Google Scholar
• Crowe JE Jr. Recent advances in the study of human antibody responses to influenza virus using optimized human hybridoma approaches. Vaccine 2009; 27:47 - 51
   Web of Science ®Google Scholar
• Shannon-Lowe C, Baldwin G, Feederle R, Bell A, Rickinson A, Delecluse HJ. Epstein-Barr virus-induced B-cell transformation: quantitating events from virus binding to cell outgrowth. J Gen Virol 2005; 86:3009 - 3019
   PubMed Web of Science ®Google Scholar
• Aman P, Ehlin-Henriksson B, Klein G. Epstein-Barr virus susceptibility of normal human B lymphocyte populations. J Exp Med 1984; 159:208 - 220
   PubMed Web of Science ®Google Scholar
• Miller G, Lipman M. Release of infectious Epstein-Barr virus by transformed marmoset leukocytes. Proc Natl Acad Sci USA 1973; 70:190 - 194
   PubMed Web of Science ®Google Scholar
• Kanbe E, Zhang DE. A simple and quick method to concentrate MSCV retrovirus. Blood Cells Mol Dis 2004; 33:64 - 67
   PubMed Web of Science ®Google Scholar
• O'Doherty U, Swiggard WJ, Malim MH. Human immunodeficiency virus type 1 spinoculation enhances infection through virus binding. J Virol 2000; 74:10074 - 10080
   PubMed Web of Science ®Google Scholar
• Ferrari S, Mudde GC, Rieger M, Veyradier A, Kremer Hovinga JA, Scheiflinger F. IgG subclass distribution of anti-ADAMTS13 antibodies in patients with acquired thrombotic thrombocytopenic purpura. J Thromb Haemost 2009; 7:1703 - 1710
   PubMed Web of Science ®Google Scholar
• Harding FA, Stickler MM, Razo J, DuBridge RB. The immunogenicity of humanized and fully human antibodies. mAbs 2010; 2:256 - 265
   PubMed Web of Science ®Google Scholar
• Richards J, Auger J, Peace D, Gale D, Michel J, Koons A, et al. Phase I evaluation of humanized OKT3: toxicity and immunomodulatory effects of hOKT3gamma4. Cancer Res 1999; 59:2096 - 2101
   PubMed Web of Science ®Google Scholar
• Kipriyanov SM, Little M. Generation of recombinant antibodies. Mol Biotechnol 1999; 12:173 - 201
   PubMed Web of Science ®Google Scholar
• Morrison SL, Johnson MJ, Herzenberg LA, Oi VT. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci USA 1984; 81:6851 - 6855
   PubMed Web of Science ®Google Scholar
• Chadd HE, Chamow SM. Therapeutic antibody expression technology. Curr Opin Biotechnol 2001; 12:188 - 194
   PubMed Web of Science ®Google Scholar
• Riechmann L, Clark M, Waldmann H, Winter G. Reshaping human antibodies for therapy. Nature 1988; 332:323 - 327
   PubMed Web of Science ®Google Scholar
• Tempest PR, Bremner P, Lambert M, Taylor G, Furze JM, Carr FJ, et al. Reshaping a human monoclonal antibody to inhibit human respiratory syncytial virus infection in vivo. Biotechnology (NY) 1991; 9:266 - 271
   PubMedGoogle Scholar
• Hillmen P, Skotnicki AB, Robak T, Jaksic B, Dmoszynska A, Wu J, et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007; 25:5616 - 5623
   PubMed Web of Science ®Google Scholar
• Collarini EJ, Lee FE, Foord O, Park M, Sperinde G, Wu H, et al. Potent high-affinity antibodies for treatment and prophylaxis of respiratory syncytial virus derived from B cells of infected patients. J Immunol 2009; 183:6338 - 6345
   PubMed Web of Science ®Google Scholar
• Sutkowski N, Rubinchik S. Human monoclonal antibodies and methods for producing the same 2007; inventor; PCT/US2008/072124
   Google Scholar
• Wulff H, Knaus HG, Pennington M, Chandy KG. K+ channel expression during B cell differentiation: implications for immunomodulation and autoimmunity. J Immunol 2004; 173:776 - 786
   PubMed Web of Science ®Google Scholar
• Siemer D, Kurth J, Lang S, Lehnerdt G, Stanelle J, Kuppers R. EBV transformation overrides gene expression patterns of B cell differentiation stages. Mol Immunol 2008; 45:3133 - 3141
   PubMed Web of Science ®Google Scholar
• Sun SQ, Guo HC, Sun DH, Yin SH, Shang YJ, Cai XP, et al. Development and validation of an ELISA using a protein encoded by ORF2 antigenic domain of porcine circovirus type 2. Virol J 2010; 7:274
   PubMed Web of Science ®Google Scholar